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Summary
Objective: Aggrecan is the major proteoglycan in articular cartilage and is known to be degraded by various proteases, including matrix metal-
loproteinases (MMPs). The present study was undertaken to develop immunoassays detecting aggrecan and its fragments generated by MMP
and non-MMP-mediated proteolysis.
Methods: Two immunoassays were developed: (1) the G1/G2 sandwich assay employing a monoclonal antibody (F-78) both as a capturing
and a detecting antibody, and (2) the 342-G2 sandwich assay substituting the capturing antibody in the G1/G2 test with a monoclonal anti-
body, AF-28 recognizing the 342FFGVG neo-epitope generated by MMP cleavage. These assays were compared to the commercially avail-
able glycosaminoglycan (GAG) assay.
Results: In supernatants of Oncostatin M and Tumor Necrosis Factor alpha (OSM/TNFa) stimulated explants, high levels of G1/G2 fragments
and GAGs were released in the initial phase (days 2e5), followed by low levels in the intermediate (days 9e12) and late phase (days 12e21).
MMP-generated fragments were detected in the late phase only. In the presence of the general MMP inhibitor GM6001, 342-G2 was not
detected, whereas the G1/G2 proﬁle remained virtually unchanged. In patients with rheumatoid arthritis (RA), the release of G1/G2 molecules
was decreased (27.3%), and that of the 342-G2 fragments increased compared to healthy controls (33.3%).
Conclusion: The stimulation of bovine articular cartilage explants with OSM/TNFa released aggrecan fragments both in an MMP and non-
MMP-mediated route. These immunoassays carry a potential as diagnostic tools for the quantitative assessment of the cartilage turnover
in RA patients in addition to their utility in ex vivo explant cultures.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
A central pathophysiological event in osteoarthritis (OA)
and rheumatoid arthritis (RA) is the irreversible destruction
of articular cartilage of the joints. Consequently, the gradual
loss of cartilage in the joints leads to pain and functional
impairment1.
In articular cartilage, chondrocytes synthesize extracellu-
lar matrix (ECM) molecules such as collagens, proteogly-
cans and hyaluronic acid. These components are
anchored in an organized and complex structure capable
of attracting and retaining large quantities of water, and
thereby acquiring the ability to resist compressive
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Received 7 April 2006; revision accepted 23 July 2006.2deformation during mechanical loading2. In RA, the chon-
drocytes concomitantly with the synovium3,4 are responsi-
ble for the degradation of the ECM by producing a wide
variety of proteases that can degrade type II collagen, ag-
grecan and other components of the cartilage matrix5e7.
To facilitate the study of chondrocyte-mediated cartilage
metabolism, several in vitro and ex vivo model systems
have been developed. In particular, the culturing of articular
cartilage explants offers the advantage of having the chon-
drocytes embedded in their natural matrix, allowing the cells
to interact within the complex environment of the cartilage8.
The degradation of type II collagen has been studied in
ex vivo cultures of bovine articular explants9,10. The release
of collagen fragments into the supernatant has been quan-
titatively assessed by immunoassays11, or alternatively, by
quantifying hydroxyproline12.
Likewise, cartilage erosion in explant cultures has been
quantiﬁed by monitoring the level of glycosaminoglycans
(GAGs) released into the supernatant13e17, or by detecting
various aggrecan fragments7,14e19. Previous identiﬁcation
and characterization of aggrecan neo-epitopes generated12
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ADAMTs (A Disintegrin and Metalloproteinase with Throm-
bospondin motifs) have been conducted mostly by Western
blotting techniques after stimulation with different pro-
inﬂammatory agents7,14e19. Immunoassays detecting neo-
epitopes of aggrecan formed by the action of MMPs and
ADAMTs have been reported by Fosang et al.20 and Pratta
and co-workers21. Though there are a number of ADAMTs
and MMP cleavage sites in aggrecan, the major MMP and
ADAMTs cleavage sites are located between IPE-
N341e342FFGV and TEGE373e374ARGS in the interglobular
domain (IGD), respectively. However, these studies have
not systematically delineated the MMP-mediated and non-
MMP-mediated release of aggrecan into the supernatant
of cartilage explant cultures by enzyme-linked immunosor-
bent assay (ELISA).
Therefore, the present study was undertaken to develop
corresponding immunoassays allowing the investigation of
MMP-mediated and non-MMP-mediated release of aggre-
can and its fragments, and to use these in the investigation
of cartilage degradation in bovine articular cartilage ex-
plants and in patients with RA.
Materials and methods
CLINICAL DATA
The clinical data were evaluated by randomly selecting 20
RA patients (age of 59 4.8 years) from a 56 week study,
who all fulﬁlled the American College of Rheumatology
(ACR) criteria for RA disease revised in 198722. All patients
were female and had early RA <2 years duration (median
duration 4months). Patients underwent drug treatment either
with leﬂunomide, methotrexate, sulfasalazine, trolovol alone,
or in combination with low dosage of corticosteroid
(5e10 mg/day prednisolone) for 2 years before they were
evaluated in the study. Patients with renal insufﬁciency
were excluded. A subset of 57 healthy age-matched women
(age of 57 2.7) were used as controls for patients with RA.
Blood was collected in tubes from fasting individuals in
the morning before 10 AM, and allowed to clot at room tem-
perature (RT) for at least 10 min. Then the collected blood
was centrifuged for 10 min at 1000g. The serum was iso-
lated from the clot, and stored at 70C, before assaying
them in two developed aggrecan assays (see below). Dis-
ease Activity Score (DAS) was 5.2 1.1 (meanSD) in
the RA patients. DAS is a validated index that includes
a count of 28 joints assessed for swelling and tenderness,
a measure of an acute-phase reactant and a measure of
global well-being23.
Anteroposterior radiographs of the hand, wrist and feet
were obtained from baseline, after 28 weeks, and at the
end of the trial. The radiographs were evaluated by two in-
dependent persons who were blinded to the treatment but
were aware of the chronological sequence of the radio-
graphs. Radiographs were scored according to the modiﬁed
Sharp/van der Heide scoring methods24. The Sharp score
was 135 87 (meanSD) in the RA patients.
REAGENTS
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (cat. num-
ber 22320-022), Roswell Park Memorial Institute (RPMI)
1640 medium (cat. number 52400-025), Hypoxanthine
and Thymidine (HT) supplement 100 (cat. number
11067-030), Hypoxanthine Aminopterin Thymidine (HAT)
supplement 50 (cat. number 21060-017), penicillin10,000 U/ml and streptomycin 10,000 mg/ml (cat. number
DE 17-602E) and Fetal Calf Serum (FCS) (cat. number
10082-147) were all purchased from Invitrogen, DK. Delﬁa
Europium (EU)-N1 labeled anti-mouse antibody (AD0124),
assay buffer (50 mM TriseHCl, 0.9%NaCl, 0.5% Bovine Se-
rum Albumin (BSA), 0.1% Tween, 20 mM ethylenediamine-
tetraacetic acid (EDTA), pH 7.8) (cat. number 1244-111)
and enhancement solution (acidic chelating detergent)
(cat. number 4001-0010) were all from Perkin Elmer. Hybrid-
oma cloning factor (contains various growth factors) (cat.
number S05-015) was bought from PAA laboratory GmBH.
The MMP inhibitor GM6001 2.5 mM (CC1000), synthetic
IGD of aggrecan 500 mg/ml (CC1890) and chicken neurocan
10 mg (AG270) and Freunds incomplete adjuvants 50 ml
(AR002) were all from Chemicon, USA. Tumor Necrosis
Factor alpha (TNFa) 10 mg/ml (cat. number 210-TA) and
MMP-13 (cat. number 511-MM) were bought from R and D
systems. Maxisorp plates were purchased from Nunc. (cat.
number 439454), while streptavidin coated plates were
bought from Roche (cat. number 1207733). Puriﬁed bovine
aggrecan 1 mg (A-1960), Chondroitinase ABC Lyase
0.3e3 U/mg solid (C2905), oncostatin M (OSM) 10 mg/ml
(O9635-10UG), Pepstatin A (P5318) 10 mg, p-aminophenyl-
mercuric acetate (APMA) 5 g (A-9563), MMP-2 200 mg/ml
(M-7942), MMP-9 200 mg/ml (M-4809) and gelatine 100 g
from bovine skin (G9382) were all from Sigma Aldrich, DK.
DEVELOPMENT OF MONOCLONAL ANTIBODIES TO THE G1/G2
DOMAIN OF AGGRECAN
Eight to 10-week-old Balbc/A mice were immunized sub-
cutaneously every second week for 2 months and subse-
quently monthly with 50 mg per dose of puriﬁed bovine
intact aggrecan emulsiﬁed in an equal volume of Freunds
incomplete adjuvant. Serum from immunized mice was col-
lected, and the titer of anti-aggrecan antibodies assessed
by ﬂuorescence immunoassay. This was done by coating
maxisorp plates overnight (ON) at 4C with 100 ml chondroi-
tinase-treated aggrecan diluted to 25 ng/ml in coating buffer
(10.6 mM Na2CO3, 39.3 mM NaHCO3, 3.1 mM NaN3, pH
9.6). The plates were washed ﬁve times with washing buffer
(0.15 M NaCl, 0.05% (v/v) Tween 20). Subsequently, 100 ml
of mice serum serial diluted in Phosphate Buffered Solution
with Bovine Serum Albumine and Tween (PBS-BTB) was
added to the wells, and the plate was incubated for 1 h at
4C with shaking at 300 rpm. After washing as described
above, 100 ml of 0.5 mg/ml Delﬁa EU-labeled secondary
anti-mouse antibody diluted in assay buffer was added to
the wells, and the plate was incubated for 1 h at 4C with
shaking. After washing the plate ﬁve times, 150 ml enhance-
ment solution (acidic chelating substrate solution for determi-
nation of formed EU3þ/Sm3þ ions in solution in ﬂuorescence
ELISA, Perkin Elmer) was added, and after incubating the
plate for 15 min at RT with shaking, the ﬂuorescence was
measured with a wallas victor2 1420 multilabeled counter.
Mice with high aggrecan antibody titers were intra-perito-
neally injected with 50 mg of puriﬁed bovine aggrecan 3
days before fusion. Fusion was performed after standard
procedures with ECACC Xþ4P P3X63.Ag8-653 myeloma
cells as previously described25.
Supernatants from hybridoma cells were screened for the
presence of anti-aggrecan antibodies as described above.
Hybridomas from wells containing anti-aggrecan antibodies
were selected and cloned twice by limiting dilution. Subse-
quently, themonoclonal antibodieswereevaluated inaseries
of immunoassays. Brieﬂy, antibodies recognizing puriﬁed
porcine G1/G226 (material characterized in Ref. [26]), but
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in a sandwich construction with the monoclonal antibody
AF-28, recognizing the N-terminal neo-epitope 342FFGVG
(see below). One monoclonal antibody, i.e., F-78, was
selected for further development.
SPECIFICITY INVESTIGATIONS OF F-78
Cross-reactivity to other proteoglycans was investigated
by competition G1/G2 ELISA. Shortly, 100 ml 1000 ng/ml bi-
otinylated bovine aggrecan was incubated on streptavidin
coated plates for 1 h at 20C with shaking (300 rpm). After
washing the plates ﬁve times, 50 ml 10,000 ng/ml of aggre-
can, biglycan, BSA, decorin or neurocan were added to the
wells at the same time as 100 ml 300 ng/ml peroxidase
(POD)-labeled F-78. After incubating the plates for 1 h at
20C with shaking (300 rpm), they were washed ﬁve times,
and 100 ml of 3,30,5,50-tetramethylbenzidine solution (TMB)
substrate was added, and the plates were incubated for
15 min at 20C with shaking in the dark. Finally, 100 ml of
0.18 M H2SO4 was added to the wells, and the absorbance
was measured at 450 nm.
To further characterize the speciﬁcity of F-78, the G1/G2
sandwich assay (see below) was also run with puriﬁed por-
cine G127 (material described in Ref. [26]) at a concentration
of 1000 ng/ml. As a negative control, BSA at the same con-
centration was used.
BOVINE ARTICULAR CARTILAGE EXPLANTS
Bovine articular cartilage was obtained from the stiﬂe
joints of a 15-month-old bovine from the local slaughtery.
Pieces of cartilage (14 2 mg) were placed in 96-well
plates and incubated for 18 days at 37C with 5% CO2
and shaking (50 rpm). Serum-free DMEM was used. Ex-
plants were incubated with (1) medium alone, (2) 10 ng/ml
OSM and 20 ng/ml TNFa of the pro-inﬂammatory cytokines
in combination28, or (3) Oncostatin M and Tumor Necrosis
Factor alpha (OSM/TNFa) plus 10 mM (physiologically rele-
vant concentration)18 of the MMP inhibitor GM600129,30. As
a negative control, cartilage was metabolically inactivated
(MI) by freezing in liquid N2, and thawed at 37
C in water-
bath for three repeated freezeethaw cycles. The explant
culture medium was replaced every second to third day
for 18 days, and six independent replicates were set up of
each condition. The corresponding supernatants were
pooled, and stored at 20C until further analysis. Concen-
trations reported are subtracted from the negative control.
DETECTION OF AGGRECAN FRAGMENTS CONTAINING G1/G2
Monoclonal antibody F-78 was used in a sandwich con-
struction as both a capturing and a detecting antibody, for
the quantiﬁcation of aggrecan or its fragments containing
G1 and/or G2 molecules. Streptavidin coated plates were
incubated for 1 h at 20C with 100 ml of biotinylated F-78 di-
luted to 1800 ng/ml in PBS-BTB buffer. Plates were incu-
bated with shaking (300 rpm), and then washed ﬁve times
with washing buffer (0.15 mol/l NaCl, 0.05% (v/v) Tween
20). Subsequently 100 ml standards (puriﬁed bovine aggre-
can 0.0625e1 ng/ml), kit control (puriﬁed bovine aggrecan
0.5 ng/ml) or unknown samples (explant supernatants or
serum samples) were added, and the plates were incubated
for 1 h at 20C with shaking. After the incubation period, the
plates were washed ﬁve times as described above, and
100 ml of POD-labeled F-78 antibody diluted to 2000 ng/ml
in PBS-BTB was added. After incubating for 1 h at 20Cwith shaking, the plates were washed ﬁve times and
100 ml of TMB substrate was added, and the plates were in-
cubated for 15 min at 20C with shaking in the dark. Finally,
100 ml of 0.18 M H2SO4 was added to the wells, and the ab-
sorbance was measured at 450 nm.
DETECTION OF AGGRECAN FRAGMENTS CONTAINING 342-G2
Monoclonal antibody AF-28 recognizing the N-terminal
neo-epitope generated by proteolytic cleavage of the amino
acid sequence DIPEN341e342FFGVG localized in the IGD
has previously been described20. The 342-G2 test was
very similar to the G1/G2 test described above except that
the capturing antibody, i.e., biotinylated F-78, was
substituted with biotinylated AF-28 at a concentration of
1500 ng/ml in PBS-BTB. In addition, MMP-13 digested puri-
ﬁed porcine laryngeal aggrecan diluted from 46e3000 ng/ml
in PBS-BTB was used as standards. Furthermore, run sam-
ples were kit control (FCS 1500 ng/ml) or unknown samples
(explant supernatants or serum samples).
For the digestion of porcine laryngeal aggrecan 50 ml of
5 mg/ml aggrecan was digested with 25 ml of 400 nM
MMP-13 (1 mM APMA activated ON at 37C) with the pro-
teinase inhibitors 7 ml of 0.1 mg/ml Pepstatin, and 1 ml of
20 mM E-64 in 417 ml MMP buffer (50 mM TriseHCl, pH
7.5, 10 mM CaCl2, 0.15 M NaCl, 0.05% Brij35). Digestion
was done ON at 37C with gentle shaking.
TECHNICAL PERFORMANCE
Brieﬂy, for the determination of intra-assay, samples were
run in 24 replicates, and their average was calculated on
the basis of this. For determining the inter-assay, each sam-
ple was run as double replicates at 10 independent days,
and the average was calculated.
DETECTION OF GAGs
For detection of sulfated GAGs, the quantitative dye-bind-
ing assay for in vitro analysis of GAG release was used ac-
cording to the manufacturer’s instructions (Wieslab,
Sweden). Brieﬂy, 50 ml of samples (explant supernatants),
standards (chondroitin sulfate-6 12.5e400 mg/ml), blank
(water), and kit control (cartilage extract diluted in water)
were pipetted into a vial and 50 ml 8 M GuanidineeHCl
was added. The vials were incubated for 15 min at RT. After
incubation, 50 ml SAT solution (0.3% H2SO4 and 0.75% Tri-
ton X-100) was added into each vial and they were incu-
bated for 15 min at RT. 750 ml Alcian Blue (0.3%) working
solution (0.1% H2SO4 and 0.4 M GuHCl) was added, the
contents were mixed, and incubated for 15 min at RT. After
incubation, the pellet was isolated by centrifugation for
15 min at 12,000g. MSO solution (40% dimethylsulphoxide
and 0.05 M MgCl2) (500 ml) was added, and mixing was
done thoroughly on a shaker for 15 min at RT. This was fol-
lowed by centrifugation for 15 min at 12,000g, and the su-
pernatant was removed. GueProp solution (4 M GuHCl,
33% 1-propanol and 0.25% Triton X-100) (500 ml) was
added to the pellets and the vials were shaken for 15 min
at RT. The absorbance was read at 620 nm.
PROTEOLYTIC PROCESSING OF AGGRECAN AND ITS
FRAGMENTS RELEASED INTO THE SUPERNATANT
All reactions were carried out in 0.5 ml of MMP buffer
(50 mM TriseHCl, pH 7.5, 10 mM CaCl2, 0.15 M NaCl,
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from day 5 and day 18 (see the section on Bovine articular
cartilage explants) were selected for sensitivity to further
proteolytic processing with MMPs. Each supernatant was
incubated with either MMP-2 or MMP-9 activated by incuba-
tion with 1 mM APMA ON at 37C. After activation, 10 ml of
enzyme suspension was added to 50 ml of the supernatant
in a ﬁnal concentration of 100 nM MMP-2 or MMP-9 and
440 ml buffer, and the solutions were incubated for 24 h at
37C under gentle agitation. After incubation, the reaction
was stopped by adding 20 ml of 250 mM GM6001 and stored
frozen until further analysis.
ZYMOGRAPHY
MMP expression and activity was determined by gelati-
nase zymography using 0.5 mg/ml of gelatine as a substrate
in 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gels.
A volume of 5 ml of culture supernatant was loaded on the
zymography gels, and the proteins were separated. After
electrophoresis, the gels were washed three times with
2.5% Triton X-100 in water and then incubated ON at
37C in 0.1% Triton X-100, 5 mM CaCl2, 1 mM ZnCl2,
3 mM NaN3, 50 mM Tris pH 7.4 in a closed container. Gels
were stained for 30 min with 0.25% Coomassie R-250 in
10% acetic acid and 45% methanol and destained for
30 min with 20% acetic acid, 20% methanol, 17% ethanol,
and 0.6% diethylether. Gels were dried and scanned for
documentation.
HISTOLOGY
The bovine articular cartilage explants were stimulated
with OSM/TNFa and ﬁxed in 3.7% formaldehyde in PBS
pH 7.4, parafﬁn embedded, and subsequently sectioned
into 5 mm sections. The proteoglycans were stained
with toluidine blue after deparafﬁnization and rehydration.
The sections were counterstained with Erlich’s hematox-
ylin. Digital histographs were taken using an Olympus
BX-60 microscope and an Olympus C5050 zoom
camera.
Results
DEVELOPMENT OF IMMUNOASSAYS FOR AGGRECAN
Monoclonal antibody F-78 was raised against intact bo-
vine aggrecan, and its speciﬁcity was tested by a competi-
tion G1/G2 ELISA. The antibody was particularly speciﬁc to
aggrecan, and showed no appreciable cross-reactivity to bi-
glycan and decorin, while F-78 demonstrated low reactivity
to neurocan [Fig. 1(A)]. To further characterize its speciﬁc-
ity, it was incorporated into a sandwich immunoassay. Re-
activity of puriﬁed porcine G1 domain was observed in the
sandwich ELISA [Fig. 1(B)].
For detection of MMP-generated aggrecan fragments,
a sandwich assay with AF-28 as capturing antibody was de-
veloped. Reactivity of puriﬁed MMP digested porcine aggre-
can was detected [Fig. 1(C)].
The technical performance of both the G1/G2 and 342-
G2 sandwich tests was investigated (Table I). Both tests
had intra- and inter-assay variations in the range
5.8e8.9%, and the linearity was between 103.9e116.9%
and 95.7e98.1% for the G1/G2 and the 342-G2 tests re-
spectively. These two tests [Fig. 2(A and B)] were com-
pared to the test for total GAGs.Ag
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Fig. 1. (A) To investigate the speciﬁcity of F-78, intact puriﬁed bovine
aggrecan, chicken neurocan, BSA as a negative control, bovine
biglycan and bovine decorin were run in the G1/G2 competition
assay at a concentration of 10,000 ng/ml. The values are meanþ
S.E.M.s, and the asterisks indicate signiﬁcant differences. For the
statistical analysis, unpaired t test with Welch’s correction was
used with one-tailed P values. (B) To investigate the speciﬁcity of
F-78, puriﬁed porcine G1 and BSA as a negative control were run
in the G1/G2 sandwich assay at a concentration of 1000 ng/ml.
The values are meanþ S.E.M.s, and the asterisks indicate signiﬁcant
differences. For the statistical analysis, unpaired t test with Welch’s
correction was used with one-tailed P values. (C) To investigate the
speciﬁcity of F-78, puriﬁed MMP digested porcine aggrecan was run
in the 342-G2 sandwich assay at a concentration of 1000 ng/ml, and
as a negative control BSAwas used. The values are meanþ S.E.M.s,
and the asterisks indicate signiﬁcant differences. For the statistical
analysis, unpaired t test with Welch’s correction was used with
one-tailed P values.
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ARTICULAR CARTILAGE EXPLANTS
Explants, all in the range of 12e16 mg, from bovine artic-
ular cartilage were isolated, and conditioned medium from
pooled supernatants (low variability) stimulated with OSM/
TNFa demonstrated an increase in the release of 342-G2
fragments in the late phase after day 12 (Fig. 3). The ele-
vated release in the late phase was completely abrogated
in the presence of the MMP inhibitor GM6001. Under the
same experimental conditions, the release of G1/G2 had
a different proﬁle with elevated release in the early phase
approaching background levels in the mid and late phase.
The G1/G2 proﬁle was not diminished in the presence of
MMP inhibitor (Fig. 3). However, total GAG release into
the supernatant had a proﬁle similar to the G1/G2 proﬁle,
with elevation in the initial phase only (Fig. 4). Supernatants
obtained from MI cartilage explants, or explants kept in me-
dium without catabolic cytokines, contained less than
around 10 mg/ml of aggrecan or aggrecan fragments
throughout the whole period (data not shown).
EXPRESSION AND ACTIVITY OF MMP-2 AND MMP-9 INDUCED
BY TNFa AND OSM STIMULATION OF BOVINE ARTICULAR
CARTILAGE EXPLANTS
We investigated the expression and activity of gelati-
nases by zymography of explant supernatants stimulated
Table I
Technical performance of the G1/G2 and the 342-G2 tests
Total aggrecan
turnover
Aggrecan
degradation
G1/G2 assay 342-G2 assay
Measuring range 0.063e1.000 ng/ml 46e3000 ng/ml
Lower Detection Limit (LDL) 0.010 ng/ml 10 ng/ml
Intra-assay (n¼ 24) (mean;
coefﬁcient of variation)
0.781 ng/ml;
7.1%
995 ng/ml; 7.5%
Inter-assay (n¼ 10) (mean;
coefﬁcient of variation)
0.22 ng/ml;
8.9%
816 ng/ml; 5.8%
Dilution recovery (mean;
range)
110.4%;
103.9e116.9%
96.8%;
95.7e98.1%
A
B
Fig. 2. (A) The G1/G2 assay detecting intact aggrecan and aggre-
can fragments carrying the G1 and/or G2 domain, (B) 342-G2 as-
say detecting aggrecan fragments carrying both the 342FFGVG
neo-epitope and the G2 globular domain.with OSM/TNFa (Fig. 5). While the pro-enzymes of MMP-
2 and MMP-9 were expressed at early days in the superna-
tants of OSM/TNFa stimulated bovine cartilage explants,
the active enzymes were detected from day 14 (MMP-2)
and day 12 (MMP-9) and onwards. As control for MMP ac-
tivity, the gelatine zymography was incubated with
GM6001, which completely blocked gelatinase activity
(data not shown). The molecular weight marker showed
the bands corresponding to the weights of pro MMP-9
92 kDa, active 86 kDa and pro MMP-2 72 kDa and active
66 kDa.
FURTHER PROTEOLYTIC PROCESSING OF AGGRECAN AND
ITS FRAGMENTS RELEASED INTO SUPERNATANTS OF
CARTILAGE EXPLANTS
To investigate the effect of further proteolytic degradation
on the reactivity in the immunoassays, we treated the con-
ditioned medium, originating from the cartilage explant
cultures described above with MMP-2 (data shown) and
MMP-9 (data not shown). Upon MMP-2 treatment of super-
natants stimulated for 5 days with OSM/TNFa, the level of
G1/G2 was reduced from 193 mg/ml to 149 mg/ml (statisti-
cally signiﬁcant reduction of 23%) [Fig. 6(A)], whereas no
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Fig. 3. Bovine articular cartilage explants were stimulated with the
cytokines OSM/TNFa and supernatants were measured for the
presence of aggrecan and aggrecan fragments by immunoassays.
G1/G2 assay with (- -) and without (-,-) the general MMP inhib-
itor GM6001. 342-G2 assay with (-C-) and without (-B-) GM6001.
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Fig. 4. The level of total GAGs (-,-) in explant cultures stimulated
with OSM/TNFa.
217Osteoarthritis and Cartilage Vol. 15, No. 2Fig. 5. Gelatinase activity investigated by zymography of conditioned medium from cartilage explants treated with OSM/TNFa. Lane
A: Vehicle, conditioned medium without cytokines from day 12. Lane B: Conditioned medium from MI explants from day 12. The rest of
the lanes represent conditioned medium of explants stimulated with OSM/TNFa at days 2, 5, 7, 9, 12 and 14. Active and pro-enzymes
were identiﬁed by comparison to the molecular markers and MMP-2 and MMP-9 standards (not shown). The molecular weight marker showed
the bands corresponding to the weights of pro MMP-9 92 kDa, active 86 kDa and pro MMP-2 72 kDa and active 66 kDa.change was observed in the 342-G2 test [Fig. 6(C)]. When
treating OSM/TNFa stimulated supernatants from day 18
with MMP-2, no difference was observed in the level of
G1/G2 [Fig. 6(B)] or 342-G2 [Fig. 6(D)]. Similar data were
observed by treatment of supernatants with MMP-9.
DEGRADATION OF AGGRECAN EVALUATED BY HISTOLOGY
To conﬁrm the degradation of the matrix in the explant
cultures, histology was performed on explants from day 5
and day 18 stimulated with OSM/TNFa, and proteoglycans
were stained with toluidine blue. There was an intense
staining of proteoglycans in non-stimulated or MI explants.
However, the intensity of the staining was stronglydecreased in explants stimulated with OSM/TNFa at both
day 5 and day 18 [Fig. 7(A and B)].
CIRCULATING LEVELS OF AGGRECAN AND ITS FRAGMENTS
IN PATIENTS WITH RA
In order to determine, if the G1/G2 and 342-G2 assays
could have potential as clinical diagnostic tools, the aggre-
can level was determined in healthy controls as well as in-
dividuals diagnosed with RA. The concentration of G1/G2
was signiﬁcantly decreased in patients with RA compared
to controls (P¼ 0.0001) [Fig. 8(A)], while the level of 342-
G2 was elevated in RA individuals, though not signiﬁcant
[Fig. 8(B)]. To further evaluate, if there was a signiﬁcantBuffer +MMP2 +MMP2+GM6001
0
100
200
300
*
***
P=0.021
P=0.0002
A
g
g
r
e
c
a
n
 
t
u
r
n
o
v
e
r
 
G
1
-
G
2
 
(
μ
g
/
m
l
)
A
g
g
r
e
c
a
n
 
t
u
r
n
o
v
e
r
 
G
1
-
G
2
 
(
μ
g
/
m
l
)
Buffer +MMP2 +MMP2+GM6001
0
2
4
6
8
10
Buffer + MMP2 +MMP2+GM6001
0
2
4
6
8
10
Buffer +MMP2 +MMP2 + GM6001
0
1
2
3
4
5
6
A
g
g
r
e
c
a
n
 d
e
g
r
a
d
a
t
i
o
n
 
3
4
2
-
G
2
(
μ
g
/
m
l
)
A
g
g
r
e
c
a
n
 d
e
g
r
a
d
a
t
i
o
n
 
3
4
2
-
G
2
(
μ
g
/
m
l
)
A B
C D
Fig. 6. Articular cartilage explants were stimulated with OSM/TNFa for 5 days (see Fig. 3) and supernatants were subsequently treated with
either buffer, MMP-2 or MMP-2 with MMP inhibitor (GM6001) and measured in the G1/G2 assay (A) or 342-G2 (C). Similar supernatants from
day 18 were measured in the G1/G2 (B) and 342-G2 assays (D). The values are meanþ S.E.M.s, and the asterisks indicate signiﬁcant differ-
ences. For the statistical analysis, unpaired t test with Welch’s correction was used with one-tailed P values.
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Fig. 7. Bovine articular explants were cultured in the presence (OSM/TNFa) or absence of cytokines (W/O) for 5 days (A) or 18 days (B) and
subsequently ﬁxed in formaldehyde and parafﬁn embedded. Sections were stained for proteoglycans by toluidine blue, and as a negative con-
trol, MI explants were also included.difference in controls compared to RA patients in the level
of degraded aggrecan of the total pool of aggrecan mole-
cules, the aggrecan index 342-G2/G1/G2 was calculated.
A signiﬁcant increase (P¼ 0.0074) [Fig. 8(C)] was detected
in RA individuals compared to healthy controls.
Discussion
In the present study, we have demonstrated that cata-
bolic stimulation of bovine explant cultures leads to both
MMP and non-MMP-mediated release of aggrecan frag-
ments into the supernatant, and that these fragments can
be quantitatively assessed by novel immunoassays.
To facilitate the investigation of aggrecan degradation in
the cartilage matrix, new monoclonal antibodies were devel-
oped to intact aggrecan, and a series of novel immunoas-
says were developed. In particular, one monoclonal
antibody, F-78, speciﬁc to aggrecan [Fig. 1(A)], recognizing
a repetitive epitope exposed at least once on G1 [Fig. 1(B)]
was selected for development of two complementary immu-
noassays. The G1/G2 assay employing F-78 both as a cap-
turing and a detecting antibody quantiﬁes intact aggrecan,
as well as fragments containing G1 and/or G2, whether
these fragments are being generated by MMPs or other pro-
teases [Fig. 2(A)]. In contrast, the 342-G2 assay, using
a monoclonal antibody recognizing an MMP-generated
neo-epitope as a capturing antibody, detects the subpopu-
lation of G2-containing molecules, carrying the neo-epitope
342FFGVG as well [Fig. 2(B)]. Previously Fosang et al. used
this neo-epitope speciﬁc antibody, and developed a compet-
itive assay with a sensitivity of 7 pmol/ml31. The sensitivity
of the 342-G2 assay is 10 ng/ml (Table I), which corre-
sponds to 0.33 pmol/ml, and this assay is therefore around
20 times more sensitive than the competition assay. More-
over, detection of the 342FFGVG neo-epitope in serum has
never been reported before, implying that a highly sensitive
system is required to detect this analyte.
Various in vitro32e34 and ex vivo14e16 models have been
used for the study of cartilage metabolism. However, thearticular cartilage explant model is particularly useful, as it
allows the preservation of the chondrogenic phenotype.
Furthermore, it is widely used as a degradation model for
the study of cytokine-stimulated chondrocytes, embedded
in their natural cartilage matrix, and has served as a model
for the investigation of medical intervention of chondropro-
tective drugs8. In particular, the bovine explant system,
stimulated with the catabolic cytokines OSM/TNFa has
been used to study the pathological destruction of cartilage
tissue12,27.
In the present study, OSM/TNFa induced MMP expres-
sion was detected in the late phase, i.e., after day 12 as ver-
iﬁed by zymography, and was observed concomitantly with
the emergence of 342FFGVG containing G2 aggrecan frag-
ments in the supernatant, peaking at a concentration of
around 4.5 mg/ml/mg cartilage (Fig. 3). In contrast, the initial
high levels (250e350 mg/ml/mg cartilage) of G1/G2 contain-
ing analytes were reduced to background levels before
MMP-2 and MMP-9 activity could be detected (Figs. 3
and 5). This suggests that the release of aggrecan mole-
cules from the explant cultures, which can be detected in
the supernatant in the G1/G2 assay, is caused by metabolic
events not involving MMPs. The absence of any major ef-
fect of MMP inhibitors on the G1/G2 proﬁle in the culture su-
pernatants further supports this (Fig. 3). These results are
consistent with other published data proving a role for
ADAMTs enzymes in the early release of aggrecan from
cartilage explants15e17.
It is our hypothesis that in the supernatants at day 5, two
populations of molecules exist. First, small aggrecan frag-
ments generated by proteolytic cleavage by ADAMTs, and
which contain either G1 or G2. Second, larger molecules
containing both G1 and G2 are likely to be present, as fur-
ther MMP cleavage reduces the read out in the G1/G2
ELISA [Fig. 6(A)]. We have used 100 nM of MMPs to in-
vestigate the further processing of analytes, while many
other investigators priorly have used in the range of
0.35e2.45 nM 33,35,36. The high concentration of MMPs
will separate all FFGVG epitopes from the G2 domain,
and therefore will remain undetected by the 342-G2 ELISA
219Osteoarthritis and Cartilage Vol. 15, No. 2[Fig. 6(C)]. However, the presence of the signal at day 18 in
the 342-G2 ELISA, when exogenously treating explant su-
pernatants with MMPs [Fig. 6(D)], is explained by the lack
of activity of enzymes against other minor MMP regions in
IGD, once a clipping has already occurred at the IPE-
N341e342FFGV site. Mercuri et al. observed that MMP de-
rived G2 fragments of aggrecan are indeed resistant to
further aggrecanase cleavage in IGD37, which may be the
case for the MMP sites as well. Moreover, the substrate:en-
zyme ratio most likely has an inﬂuence on the cleavage of
the IGD at the major IPEN341e342FFGV MMP site or multi-
ple sites, with a high ratio in the early, and low ratio in the
late phase.
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Fig. 8. Serum samples from healthy individuals (n¼ 57) and pa-
tients with RA (n ¼ 20) were analyzed in the G1/G2 assay (A)
and the 342-G2 assay (B). The aggrecan degradation index (C)
was obtained by dividing the concentration of 342-G2 with the level
measured in the G1/G2 assay for both healthy individuals and RA
patients. For standardization of samples in the G1/G2 assay, intact,
puriﬁed bovine aggrecan at concentrations 0.0625e1 ng/ml was
used, whereas MMP treated puriﬁed porcine aggrecan at concen-
trations 46e3000 ng/ml was used in the 342-G2 assay. The values
are meanþ S.E.M.s, and the asterisks indicate signiﬁcant differ-
ences. For the statistical analysis, unpaired t test with Welch’s cor-
rection was used with one-tailed P values.When intact G1/G2 is cleaved in IGD, this will theoreti-
cally cause a 33% reduction in the G1/G2 test read out.
This is because, molecules containing both G1 and G2
could bind one biotinylated antibody and 3 peroxidase la-
beled antibodies (due to the same repetitive epitope in G1
and G2), whereas separation of G1 and G2 produces mol-
ecules binding one peroxidase labeled antibody per 1
biotinylated antibody. Consequently, the reduction of
approximately 23% in the G1/G2 test, which is observed
in MMP treated supernatants could correspond to cleavage
of intact G1/G2 [Fig. 6(A)].
Degradation of aggrecan has been extensively investi-
gated through in vivo15,31,38, in vitro7,32e34,39, and in ex
vivo cultures of cartilage explants14e16,40,41. These studies
demonstrate, that besides the MMPs, a second important
class of enzymes, i.e., the aggrecanases are capable of de-
grading aggrecan42. A primary site for these proteases is
the sequence TEGE373e374ARGS in the IGD sequ-
ence18,38,42. Two aggrecanases, aggrecanase 1 and aggre-
canase 2, also designated ADAMTS-415 and ADAMTS-515
respectively are considered to be active in the early
stages of cartilage erosion in OA as well as RA38,42. The
detection of the epitopes TEGE373 and 374ARGS by
western blotting has been reported in the early phase of
explants treated with pro-inﬂammatory agents like TNFa,
interleukin 1 or retinoic acid12,16,40,43. Malfait et al. state
that when they use the MMP inhibitor XS309, the activity
of ADAMTS-4 and ADAMTS-5 is not blocked at concentra-
tions around 10 mM, but is suppressed by the ADAMTs
inhibitor BB-1618.
These studies support our observation, that the release of
aggrecan fragments in the early phase is not mediated by
MMPs, but rather by aggrecanases. Cleavage at the
373e374 site would generate fragments that upon treat-
ment with MMPs cannot produce molecules recognized in
the 342-G2 assay as described in the present study.
In contrast, the release of aggrecan fragments in the late
phase of the OSM/TNFa stimulated explant cultures seems
to be driven by MMPs, which was shown to be elevated by
zymography from day 12 (Fig. 5). A steep elevation in the
release of 342-G2 containing fragments was observed,
and this could be completely abrogated upon incubation
with an MMP inhibitor. In addition, MMP processing of the
aggrecan fragments seemed to be complete in the late
phase, as the addition of MMP-2 or MMP-9 to culture super-
natant did not generate further 342-G2 detection [Fig. 6(D)].
The proﬁle of the total GAG release of OSM/TNFa treated
explants was similar to the trend observed in the G1/G2 as-
say, reaching maximum levels at day 5 (Fig. 4). However,
much higher concentrations were detected in the GAG as-
say. This could be explained by the fact that around 90%
of the molecular weight of aggrecan is made up by
GAGs2, while the rest is made up by the core protein. Other
proteoglycans are detected by the GAG assay, but the con-
tribution of these is negligible compared to aggrecan.
In order to further evaluate the G1/G2 and 342-G2 as-
says, our next approach was to investigate their clinical rel-
evance. A cohort of 20 women with RA were compared to
57 healthy age-matched women. We measured serum
samples in the G1/G2 and 342-G2 assays and observed
a signiﬁcant decrease (P¼ 0.0001) in the level of G1/G2
in RA patients compared to healthy controls [Fig. 8(A)], sug-
gesting a suppression of total release of G1 and G2 con-
taining aggrecan fragments. Furthermore, we showed that
we could partly decrease the signal of G1/G2 after exoge-
nously adding MMPs to explant supernatants [Fig. 6(A)].
These results support each other, as it is expected that
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MMPs44,45. This suppression of overall aggrecan turnover
could be caused by the anti-inﬂammatory treatment in the
RA patients. On the other hand, the calculated aggrecan
degradation index, which is a measure of the amount of
MMP degraded aggrecan compared to the total pool of ag-
grecan molecules (342-G2/G1/G2) showed a signiﬁcant in-
crease (P¼ 0.0074) in RA patients compared to controls
[Fig. 8(C)]. The observation done by Struglics and co-
workers of free G1 and G2 domains of aggrecan, as well
as G1/G2 and 342FFGVG-G2 molecules in different frac-
tions of synovial ﬂuid from OA patients, furthermore sup-
ports the existence of these molecules in the circulation of
arthritic individuals32.
Hence, in this study, we have developed the MMP-medi-
ated and non-MMP-mediated assays 342-G2 and G1/G2.
These assays hold noteworthy potential as important diag-
nostic tools for assessing cartilage turnover in patients diag-
nosed with RA, as well as the effects of intervention with
potential chondroprotective agents.
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